Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026)

Sarepta Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $116.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 158.67% year-over-year to $116.0 million; the TTM figure through Mar 2026 stood at $116.0 million (up 158.67% YoY), while the FY2025 annual figure was $443.4 million, up 240.4% from the prior year.
• Current Deferred Revenue was $116.0 million for Q1 2026 at Sarepta Therapeutics, down from $443.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $485.4 million in Q3 2025 to a low of $22.5 million in Q3 2023.
• Historically, Current Deferred Revenue has averaged $148.2 million across 5 years, with a median of $89.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue slumped 74.79% in 2023, then jumped 464.6% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $89.2 million in 2022, then sank by 43.51% to $50.4 million in 2023, then soared by 158.36% to $130.3 million in 2024, then soared by 240.4% to $443.4 million in 2025, then slumped by 73.83% to $116.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $116.0 million (Q1 2026), $443.4 million (Q4 2025), and $485.4 million (Q3 2025), per Business Quant data.